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Question 1
Answer: c. Approximately one third of patients treated for depression do not respond satisfactorily to first-line antidepressant pharmacotherapy. There is some evidence to show that approximately 50% of patients who do not respond to their first treatment are likely to respond to the second antidepressant (irrespective of whether it comes from the same class or a different one).
In a meta-analysis of 10 placebo-controlled studies evaluating vortioxetine in patients with moderate or severe depression, compared with placebo what were the numbers-needed-to-treat to achieve a response (i.e. ≥50% reduction from baseline in the Montgomery-Asberg Depression Rating Scale [MADRS] 
Question 3
Answer: b. Response and remission rates were higher with vortioxetine than placebo (odds ratio 1.7, 95% CI 1.3 to 2.1; and 1.4, 95% CI 1.1 to 1.8, respectively), with numbers-needed-to-treat of 9 and 18, respectively.
Mr JH discusses alternative treatments with his GP. During the discussion Mr JH asks about vortioxetine. On which receptor system is vortioxetine thought to exert its antidepressant effect? 
Question 4
Answer: b. The most common adverse events with vortioxetine are nausea and headache. Nausea usually lasts 1-2 weeks, occurs more often in women, and is the adverse event that most commonly causes patients to stop taking vortioxetine.
